Futura Medical报告,由于全球销售其勃起性机能障碍药物Eroxon的推动,它首次获得利润。 Futura Medical reports its first profit, driven by global sales of its erectile dysfunction drug, Eroxon.

英国制药公司Futura Medical(Futura Medical)报告2024年经济强劲,收入1 400万英镑,婚前利润130万英镑。 Futura Medical, a UK pharmaceutical company, reported a strong 2024 with £14 million in revenue and a maiden profit of £1.3 million. 其主要产品Eroxon在超过15个国家销售,对象是60岁以下的男子,轻度至中度勃起功能障碍。 Its main product, Eroxon, is sold in over 15 countries and targets men under 60 with mild to moderate erectile dysfunction. 该公司正在扩大其市场存在,并开发诸如Eroxon Intense和SD4000等新产品,SD4000是女性性功能障碍的热门治疗,其实验结果很有希望。 The company is expanding its market presence and developing new products like Eroxon Intense and SD4000, a topical treatment for female sexual dysfunction showing promising trial results.